Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Allergan
>
Botox will not be around 4 yrs from now. Unfortunate truth.
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="anonymous, post: 5976151"]Several analysts say RT002’s test results show it may prove a better alternative to existing short-acting toxins and could significantly cut into Botox’s sales.</p><p><br /></p><p>“People have been asking for years (for) something that can last longer than 3 months,” Dr. Joely Kaufman, a dermatologist and lead investigator in Revance’s trial, told Reuters last week.</p><p><br /></p><p>Browne declined to comment on the treatment’s likely commercial value but some analysts estimated RT002 could capture 20 percent - or more than $1 billion - of the overall botulinum toxin market in the United States by 2028, as well as a similar portion globally.</p><p><br /></p><p><br /></p><p>“We believe the biggest near-term threat (for Allergan) would be an acquisition of Revance by a major global competitor like Galderma or Johnson & Johnson (<a href="https://www.reuters.com/finance/stocks/overview?symbol=JNJ.N" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://www.reuters.com/finance/stocks/overview?symbol=JNJ.N" rel="nofollow">JNJ.N</a>),” Leerink analysts wrote in a client note last week.[/QUOTE]</p><p><br /></p>
[QUOTE="anonymous, post: 5976151"]Several analysts say RT002’s test results show it may prove a better alternative to existing short-acting toxins and could significantly cut into Botox’s sales. “People have been asking for years (for) something that can last longer than 3 months,” Dr. Joely Kaufman, a dermatologist and lead investigator in Revance’s trial, told Reuters last week. Browne declined to comment on the treatment’s likely commercial value but some analysts estimated RT002 could capture 20 percent - or more than $1 billion - of the overall botulinum toxin market in the United States by 2028, as well as a similar portion globally. “We believe the biggest near-term threat (for Allergan) would be an acquisition of Revance by a major global competitor like Galderma or Johnson & Johnson ([URL='https://www.reuters.com/finance/stocks/overview?symbol=JNJ.N']JNJ.N[/URL]),” Leerink analysts wrote in a client note last week.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Allergan
>
Botox will not be around 4 yrs from now. Unfortunate truth.
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Allergan
>
Botox will not be around 4 yrs from now. Unfortunate truth.
>